查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1883775

全球C反应蛋白检测市场

C-Reactive Protein Testing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 244 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球C反应蛋白检测市场预计到2030年将达到36亿美元。

2024年全球C反应蛋白检测市场规模估计为33亿美元，预计到2030年将达36亿美元，在分析期间（2024-2030年）内复合年增长率（CAGR）为1.7%。检测法是本报告分析的细分市场之一，预计在分析期结束时将以2.2%的复合年增长率增长至19亿美元。酵素连结免疫吸附试验（ELISA）细分市场预计在分析期间内将以1.6%的复合年增长率成长。

美国市场规模估计为8.63亿美元，而中国市场预计将以1.7%的复合年增长率成长。

预计到2024年，美国C反应蛋白检测市场规模将达8.63亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到5.809亿美元，在2024年至2030年的分析期内，年复合成长率（CAGR）为1.7%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的年复合成长率分别为1.7%和1.3%。在欧洲，德国的年复合成长率预计将达到约2.0%。

全球C反应蛋白检测市场－主要市场趋势与驱动因素概述

除了发炎之外：C反应蛋白检测究竟能说明什么？

C反应蛋白（CRP）检测是一种广泛使用的诊断工具，用于测量血液中CRP的水平。 CRP是一种由肝臟在发炎反应中产生的蛋白质。 CRP的存在与多种疾病有关，包括急性感染疾病、慢性疾病和自体免疫疾病。透过测量CRP水平，医护人员可以评估体内是否有炎症，确定发炎的严重程度，并监测治疗效果。此检测尤其重要，因为它有助于区分细菌感染和感染疾病（这两种感染都会导致CRP水平高于正常值），并指南类风湿性关节炎和克隆氏症等慢性发炎性疾病的治疗。

科技如何提高 CRP 检测的准确性和可近性？

医疗技术的进步显着提高了C反应蛋白（CRP）检测的准确性和效用。现代CRP检测可在数分钟内提供结果，从而实现快速的临床决策。尤其具有突破性的是照护现场CRP检测设备，可直接在患者床边或诊间使用。这无需将检体送往检查室，缩短了等待结果的时间。此外，微流体和生物感测技术的最新进展催生了更小巧、更灵敏的CRP检测设备，仅需少量血液样本。这降低了检测的侵入性，减轻了患者的负担。

引入CRP检测面临哪些挑战？

儘管CRP检测具有许多益处，但其应用也面临一些挑战。其中一个主要担忧是该检测可能被过度使用或误用，尤其是在CRP值无法提供明确诊断资讯的情况下。对CRP结果的误读可能导致不必要的治疗，例如对病毒感染疾病不恰当地使用抗生素。此外，虽然照护现场CRP检测具有便利性，但确保这些设备在所有医疗机构中的准确性和可靠性至关重要，但也极具挑战性。为了最大限度地发挥CRP检测的优势并避免潜在的弊端，对医护人员进行培训，使其能够有效地解读CRP检测结果并将其应用于临床实践也至关重要。

推动CRP检测市场成长的关键因素有哪些？

C反应蛋白（CRP）检测市场的成长受多种因素驱动。心血管疾病、类风湿性关节炎和发炎性肠道疾病等发炎性疾病的日益普遍，推动了对CRP检测等有效诊断和监测工具的需求。医生和患者对发炎及其在各种健康状况中的作用认识的不断提高，也促进了这一趋势。此外，照护现场技术的普及以及价格低廉、快速的CRP检测设备的广泛应用，使得更多患者能够进行此类检测。随着医疗保健系统不断强调预防性护理和早期疗育，CRP检测正逐渐成为医疗保健领域的重要工具，推动其在各种医疗机构中的应用和市场成长。

部分：

疾病类型（心血管疾病、癌症、类风湿性关节炎、发炎性肠道疾病、子宫内膜异位症、全身性红斑性狼疮、其他疾病类型）、检测类型（免疫比浊法、酵素连结免疫吸附试验、化学化学冷光免疫检测、其他检测类型）、最终用途（医院、检查室、诊所、其他最终用途）

受访公司范例

  • Abaxis, Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Laboratory Corporation of America Holdings（LabCorp）
  • Merck KgaA
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具来变革市场和竞争情报。

Market Glass, Inc. 并没有查询LLM 或产业专用的SLM 的典型方法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括视频转录、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在地、製造地以及进出口（成品和OEM产品）情况，预测企业竞争地位的变化。这种复杂多变的市场现实会从多个方面影响竞争对手，包括增加销货成本、降低盈利和重组供应链，同时也会影响微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 世界其他地区

第四章 竞赛

简介目录
Product Code: MCP11362

Global C-Reactive Protein Testing Market to Reach US$3.6 Billion by 2030

The global market for C-Reactive Protein Testing estimated at US$3.3 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2024-2030. Immunoturbidimetric Assay, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the ELISA segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$863.0 Million While China is Forecast to Grow at 1.7% CAGR

The C-Reactive Protein Testing market in the U.S. is estimated at US$863.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$580.9 Million by the year 2030 trailing a CAGR of 1.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global C-Reactive Protein Testing Market - Key Trends and Drivers Summarized

Beyond Inflammation: What Can C-Reactive Protein Testing Really Tell Us?

C-reactive protein (CRP) testing is a widely used diagnostic tool designed to measure the level of CRP in the blood, a protein produced by the liver in response to inflammation. The presence of CRP is associated with a variety of conditions, from acute infections to chronic diseases and autoimmune disorders. By measuring CRP levels, healthcare providers can assess if there is an inflammation in the body, determine its severity, and monitor the effectiveness of treatment. This test is particularly valuable because it can help distinguish between bacterial infections, which typically cause a higher CRP elevation, and viral infections, alongside guiding therapy in chronic inflammatory conditions like rheumatoid arthritis and Crohn's disease.

How Is Technology Enhancing CRP Testing Accuracy and Accessibility?

The accuracy and utility of CRP testing have significantly improved with advancements in medical technology. Modern CRP tests can deliver results in a matter of minutes, allowing for rapid clinical decision-making. Point-of-care CRP testing devices, which can be used directly at the patient’s bedside or in the doctor's office, are particularly revolutionary. They eliminate the need to send samples to a lab and reduce the waiting time for results. Moreover, recent developments in microfluidics and biosensing technologies have led to the creation of even smaller, more sensitive CRP testing devices that require only a tiny blood sample, making the test less invasive and more comfortable for patients.

What Challenges Are Faced in the Implementation of CRP Testing?

Despite its benefits, the implementation of CRP testing faces certain challenges. One of the primary concerns is the potential for overuse or misuse of the test, particularly in situations where CRP levels may not provide definitive diagnostic information. Misinterpretation of CRP results can lead to unnecessary treatments, such as the inappropriate use of antibiotics for viral infections. Additionally, while point-of-care CRP testing offers convenience, ensuring the accuracy and reliability of these devices across all healthcare settings is critical but challenging. Training healthcare providers to understand and integrate CRP test results effectively into the clinical context is also essential to maximize the test's benefits and avoid potential drawbacks.

What Key Factors Are Fueling the Expansion of the CRP Testing Market?

The growth in the C-Reactive Protein testing market is driven by several factors. The rising prevalence of inflammatory diseases such as cardiovascular disorders, rheumatoid arthritis, and inflammatory bowel disease has led to an increased demand for effective diagnostic and monitoring tools like CRP testing. Growing awareness among physicians and patients about the importance of inflammation and its role in various health conditions also contributes to this trend. Additionally, the expansion of point-of-care diagnostics and the increasing availability of affordable and rapid CRP testing devices have made these tests more accessible to a broader segment of the population. As health systems continue to emphasize preventive care and early intervention, CRP testing is positioned as a valuable tool in the medical arsenal, promoting its adoption and market growth across diverse healthcare environments.

SCOPE OF STUDY:

The report analyzes the C-Reactive Protein Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Other Disease Types); Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Other Assay Types); End-Use (Hospitals, Laboratories, Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • Abaxis, Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Laboratory Corporation of America Holdings (LabCorp)
  • Merck KgaA
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • C-Reactive Protein Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Impact of COVID-19 Pandemic and Looming Global Recession
    • What is C-reactive Protein (CRP)?
    • An Introduction to C-reactive Protein Testing
    • Global Market Prospects & Outlook
    • Immunoturbidimetric Assays: The Major Segment by Assay Type
    • hs-CRP Test Type Leads by Detection Range
    • Cardiovascular Diseases Emerge As the Leading Disease Type for CRP Testing, Cancer Detection to Make Strong Gains
    • Clinics & Hospitals Hold Dominant Share of CRP Testing Market
    • Developed Regions Lead, Developing Economies to Spur Market Growth
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prominence of POC Testing Approaches for C-reactive Protein Testing Enable Faster and Accurate Results
    • CRP Testing for Ascertaining Viral Infections
    • Growing Incidence of HIV Infections and Need for Monitoring of HIV Diseases Drive CRP Testing
    • Threat of Endometriosis in Women: Significant Role of CRP Testing
    • CRP Testing: A Vital Diagnostic Tool for Cancer
    • CRP Testing Holds Potential Role in Assessing Effectiveness of Antibiotic Drugs
    • Funding Support for Extensive Research on Applications of C-reactive Protein Testing to Boost Market Growth
    • Growing Use of CRP Testing in Cardiovascular Risk Assessment Bolsters Market Growth
    • Integration of CRP Testing in Routine Check-ups Enhances Early Detection Rates
    • Research Linking Inflammation to Various Chronic Diseases Strengthens Test Demand
    • Emerging Markets Offer Significant Opportunities Due to Expanding Healthcare Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Lupus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Immunoturbidimetric Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Chemiluminescence Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Other Assay Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 42: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 43: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 44: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 45: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 46: World C-Reactive Protein Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 98: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 107: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 116: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 125: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: UK 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 131: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 152: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of World Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of World 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of World Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of World 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of World Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of World 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION